Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : an observational studyHochmair, Maximilian J (Avtor) Morabito, Alessandro (Avtor) Hao, Desiree (Avtor) Yang, Cheng-Ta (Avtor) Soo, Ross A (Avtor) Yang, James C-H (Avtor) Gucalp, Rasim (Avtor) Halmos, Balazs (Avtor) Wang, Lara (Avtor) Golembesky, Amanda (Avtor) Märten, Angela (Avtor) Čufer, Tanja (Avtor) lung neoplasms -- therapynon-small-cell lung cancerafatinibosimertinibepidermal growth factor receptorEGFRobservational studyAim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment [>/=]10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors.Future Medicine Ltd20182020-11-09 11:24:15Neznano12623UDK: 616-006ISSN pri članku: 1744-8301DOI: 10.2217/fon-2018-0711COBISS_ID: 2048432753OceCobissID: 521824025sl2018 Maximilian Hochmair